Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: Real-life clinical experience

Future Oncology

Volumn 8, Issue 6, 2012, Pages 751-756

  Kerkhofs, Leon ^a   Boschetti, Gilles ^b   Lugini, Antonio ^c   Stanculeanu, Dana Lucia ^d   Palomo, Andrés Garcia ^e  

^a Admiraal De Ruyter Hospital   (Netherlands)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^d Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^e HOSPITAL DE LEÓN   (Spain)

Author keywords

biosimilar; cancer; chemotherapy induced anemia; epoetin

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; EXPERIENCE; HUMAN; MAJOR CLINICAL STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANEMIA; ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; ERYTHROPOIETIN; FRANCE; HEMATINICS; HEMOGLOBINS; HUMANS; ITALY; MIDDLE AGED; NEOPLASMS; NETHERLANDS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; ROMANIA; SPAIN; TREATMENT OUTCOME;

EID: 84863648640     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.39     Document Type: Article

References (24)

1. Rizzo JD, Browers M, Hurley P et al. American Society of Clinical Oncology/ American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J. Clin. Oncol. 28, 4996-5010 (2009).
2. Aapro M, Spivak JL. Update on erythropoietin-stimulating agents and clinical trials in oncology. Oncologist 14(Suppl. 1), 6-15 (2009).
3. Glaspy J, Crawford J, Vansteenkiste J et al. Erythropoiesis-stimulating agents in oncology: A study-level meta-Analysis of survival and other safety outcomes. Br. J. Cancer 102, 301-315 (2010).
4. Roger SD. Biosimilars: Current status and future directions. Expert Opin. Biol. Ther. 10, 1011-1018 (2010).
5. Weise M, Bielsky MC, De Smet K et al. Biosimilars - why terminology matters. Nat. Biotechnol. 29, 690-693 (2011).
6. Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 12, 933-980 (2011).
7. Albreht T, McKee M, Alexe DM, Coleman MP, Martin-Moreno M. Making progress against cancer in Europe in 2008. Eur. J. Cancer 44, 1451-1456 (2008).
8. Hirsch BR, Lyman GH. Biosimilars: Are they ready for primetime in the United States? J. Natl Comp. Canc. Netw. 9, 934-943 (2011).
9. Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrtions: An open-label randomized controlled trial. BMC Clin. Pharmacol. 9, 10 (2009).
10. Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Bioequivalence of HX575 (recombinant human epoetin alfa and a comparator epoetin alfa) after multiple subcutaneous administrations. Pharmacology 83, 122-130 (2009).
11. Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M. Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. Int. J. Clin. Pharmacol. Ther. 47, 397-401 (2009).
12. Haag-Weber M, Vetter A, Thyroff-Friesinger U; INJ-9 Study Group. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin. Nephrol. 72, 380-390 (2009).
13. Weigang-Köhler K, Wetter A, Thyroff- Fiesinger U. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-Associated symptomatic anaemia in patients with solid tumours. Onkologie 32, 168-174 (2009).
14. Efron B, Tibshirani RJ. An Introduction to Bootstrapping. Chapman and Hall, NY, USA (1993).
15. Ludwig H, Aapro M, Bokemeyer C et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study. Eur. J. Cancer 45, 1603-1615 (2009).
16. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoetin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J. Clin. Oncol. 22, 1301-1307 (2004).
17. Bastit L, Vanderbroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J. Clin. Oncol. 26, 1611-1618 (2008).
18. Auerbach M, Silberstern PT, Webb RT et al. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am. J. Hematol. 85, 655-663 (2010).
19. Hedenus M, Birgegård G, Näsman P et al. Addition of intravenous iron to epoetin beta increases haemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 21, 627-632 (2007).
20. Steensma DP, Sloan JA, Dakhill SR et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-Associated anemia. J. Clin. Oncol. 29, 97-105 (2011).
21. Aapro M, Beguin Y, Birgegård G, Gascón P, Hedenus M, Österborg A. Too-low iron doses and too many dropouts in negative iron trial? J. Clin. Oncol. 29, e525-e526 (2011).
22. Mhaskar R, Wao H, Kumar A et al. Role of iron supplementation to erythropoiesis-stimulating agents in the management of chemotherapy-induced anemia in cancer patients: A systematic review and meta-Analysis. Blood 116, 21 (2010) (Abstract 2055).
23. Gafte-Gvili A, Rozen-Zvi B, Vidal L et al. Intravenous iron supplementation for the treatment of cancer-related anemia: Systematic review and meta-Analysis. Blood 116, 21 (2010) (Abstract 4249).
24. IGES Institute. The competitive role of biosimilars in the German SHI market for pharmaceuticals. 2010.